EUVIMEDEUVIMED entdecken
Crossref

Serum free triiodothyronine as an adjunctive marker for thyroid hormone status in athyreotic patients on levothyroxine

Yuji Nagayama iD, Seigo Tachibana iD, Takashi Fukuda iD, Daisuke Tatsushima iD, Yusuke Mori iD, Hisakazu Shindo iD, Hiroshi Takahashi iD, Shinya Sato iD, Masahiro Nakashima iD, Hiroyuki Yamashita iD

The Journal of Clinical Endocrinology & Metabolism · 18.11.2026 · 111 (12) · 3525-3534

DOI: 10.1210/clinem/dgag220 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 17.06.2026. Verfasst von Yuji Nagayama und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Yamashita Thyroid Hospital, Fukuoka 812-0034, Japan. Hauptthemen laut MEDLINE: Thyroxine, Triiodothyronine, Hypothyroidism, Thyroid Hormones. Die Arbeit nennt 55 Literaturangaben. Gefördert von: Roche Diagnostics K.K..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Athyreotic patients receiving levothyroxine (LT4) for hypothyroidism sometimes exhibit low serum free triiodothyronine (FT3) levels despite normal TSH, and experience hypothyroid-like symptoms and signs, suggesting reduced peripheral thyroid hormone action.

Objective

The present study aimed to identify the most reliable biochemical marker for assessing peripheral thyroid hormone status in such patients.

Methods

This was a single-center retrospective, cross-sectional study of athyreotic patients on LT4. Patients were classified according to TSH, FT3 and FT4, and selected metabolic markers potentially influenced by peripheral thyroid hormone status were compared across groups.

Results

In 426 athyreotic patients taking ≥1.2 μg/kg of LT4, the majority (58%) of patients exhibited normal serum FT3 and FT4, followed by 21% with normal FT3 and elevated FT4, 18% with low FT3 and normal FT4, and 2% with low FT3 and elevated FT4. This classification corresponded well with the differences in FT3/FT4 ratios that reflect the efficiency of T4 to T3 conversion. Among 156 patients not taking anti-hyperlipidemic drugs and selected with the propensity score matching using gender as a covariate, the metabolic markers of alanine transaminase, and body mass index were significantly elevated in those with low FT3 than in those with normal FT3.

Conclusion

In our cohort, lower FT3 was associated with selected metabolic markers in LT4-treated athyreotic patients, suggesting that FT3 may provide additional information on peripheral thyroid hormone status in selected patients. Prospective studies with standardized sampling and adjustment for confounding are warranted to establish FT3 as a validated marker or support FT3-guided dosing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThyroxineTriiodothyronineHypothyroidismThyroid HormonesHumansFemaleBiomarkersCross-Sectional StudiesMaleRetrospective StudiesMiddle AgedAgedThyroid Function TestsAdultThyrotropin

Stichwörter der Autor:innen

athyreotic patientshypothyroidismperipheral thyroid hormone actionthyroxinetriiodothyronine

Substanzen

ThyroxineTriiodothyronineBiomarkersThyroid HormonesThyrotropin

Autor:innen und Institutionen

  • Department of Endocrinology, Yamashita Thyroid Hospital, Fukuoka 812-0034, Japan.
  • Department of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki 852-8523, Japan.
  • Thyroid Cancer Collaborative Research Center, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki 852-8523, Japan.
  • Department of Surgery, Yamashita Thyroid Hospital, Fukuoka 812-0034, Japan.

ORCID-Profile: Yuji Nagayama, Seigo Tachibana, Takashi Fukuda, Daisuke Tatsushima, Yusuke Mori, Hisakazu Shindo, Hiroshi Takahashi, Shinya Sato, Masahiro Nakashima, Hiroyuki Yamashita

Förderung

  • Roche Diagnostics K.K.

Zitieren

APA

Nagayama, Y., Tachibana, S., Fukuda, T., Tatsushima, D., Mori, Y., Shindo, H., Takahashi, H., Sato, S., Nakashima, M., & Yamashita, H. (2026). Serum free triiodothyronine as an adjunctive marker for thyroid hormone status in athyreotic patients on levothyroxine. The Journal of Clinical Endocrinology & Metabolism, 111(12), 3525-3534. https://doi.org/10.1210/clinem/dgag220

Vancouver

Nagayama Y, Tachibana S, Fukuda T, Tatsushima D, Mori Y, Shindo H, et al. Serum free triiodothyronine as an adjunctive marker for thyroid hormone status in athyreotic patients on levothyroxine. The Journal of Clinical Endocrinology & Metabolism. 2026;111(12):3525-3534. doi:10.1210/clinem/dgag220

BibTeX
@article{Nagayama2026,
  author = {Nagayama, Yuji and Tachibana, Seigo and Fukuda, Takashi and Tatsushima, Daisuke and Mori, Yusuke and Shindo, Hisakazu and Takahashi, Hiroshi and Sato, Shinya and Nakashima, Masahiro and Yamashita, Hiroyuki},
  title = {Serum free triiodothyronine as an adjunctive marker for thyroid hormone status in athyreotic patients on levothyroxine},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  volume = {111},
  number = {12},
  pages = {3525--3534},
  doi = {10.1210/clinem/dgag220}
}
Kostenlos starten →